Exelixis Names Dana T. Aftab as Executive Vice President of Research and Development.

Exelixis has appointed Dana T. Aftab, Ph.D., as Executive Vice President, Research and Development, overseeing all aspects of the company's drug discovery, translational research, product development, and medical affairs activities. Aftab has been with Exelixis for 25 years and played a key role in the development of CABOMETYX. Amy Peterson, M.D., has departed Exelixis as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer.

Alameda, Calif. — Exelixis, Inc. (Nasdaq: EXEL) has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development, and medical affairs activities.

Dr. Aftab, who has been with Exelixis for over 25 years, brings extensive expertise in drug discovery and development. He has been instrumental in the development of CABOMETYX® (cabozantinib), which is currently the leading tyrosine kinase inhibitor in the U.S. for both the treatment of advanced renal cell carcinoma and advanced neuroendocrine tumors. Prior to this appointment, Dr. Aftab served as Executive Vice President, Discovery and Translational Research and Chief Scientific Officer since December 2022.

The appointment of Dr. Aftab coincides with the departure of Amy Peterson, M.D., who served as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer since August 2023.

Exelixis is a globally ambitious oncology company that focuses on developing next-generation medicines and regimens at the forefront of cancer care. The company's comprehensive approach to drug discovery and development has led to a robust pipeline of small molecules and biotherapeutics, including zanzalintinib, a third-generation oral tyrosine kinase inhibitor that is the subject of multiple pivotal trials.

Forward-looking statements in this press release are based on information available to Exelixis as of the date of this release and involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements [1].

References:
[1] Exelixis, Inc. (2025). Exelixis Appoints Dana T. Aftab, Ph.D., as Executive Vice President, Research and Development. Retrieved from https://www.stocktitan.net/news/EXEL/exelixis-announces-appointment-of-dana-t-aftab-ph-d-as-executive-0gai51xf3qa3.html